Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic …MarketWatch (press release)An oral presentation (Abstract 168), entitled Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) …
Evidence Base for VELCADE Builds as new Data is Presented at 53rd American …PR Newswire UK (press release)Analyses of the phase 3 LYM3001 trial identified biomarker combinations present in a third of patients offering a significant progression free s…
Elevated doses of chemotherapy may benefit younger lymphoma patientsHemOncTodayResearchers found that an intensive form of chemotherapy — when combined with the monoclonal antibody drug rituximab (Rituxan; Genentech/Idec Pharmaceuticals) — could re…
TVs to Biologics: Samsung Dives into Biosimilars with $300M Biogen Idec JVBioWorld OnlineIt markets Tysabri (natalizumab) and Avonex (Interferon beta-1a) for multiple sclerosis, and Rituxan (rituximab) for non-Hodgkin lymphoma. Its development pipeline…
European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP …Sacramento BeeTo address the remaining major objection, the CHMP required that CTI provide a literature review of mechanisms of rituximab resistance and analyses that…
Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer TreatmentsForbesPrior to the FDA action, patients were required to get an infusion of rituximab the first day, followed by a pre-treatment diagnostic dose of radiolabeled indium-11…
Novartis highlights advances for patients with breast cancer and hematological …Reuters (press release)Everolimus – Results from a Phase II study evaluating everolimus as a monotherapy in relapsed/refractory Hodgkin lymphoma (ASH abstract #2717; Dece…
Novartis Highlights Advances for Patients With Breast Cancer and Hematological …MarketWatch (press release)Everolimus – Results from a Phase II study evaluating everolimus as a monotherapy in relapsed/refractory Hodgkin lymphoma (ASH abstract #2717; …
National experts from the John Theurer Cancer Center will present 31 studies …PhysOrg.com (press release)269 – Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non Hodgkin Lymphom…
ifaonline.co.ukNICE gives green light to cancer drugHealth Insurance and Protection MagazineRituximab (marketed as MabThera by Roche) is a targeted therapy prescribed to people with follicular lymphoma, in combination with chemotherapy treatments. Evid…